code C09CA04PubChem 3749DrugBank APRD00413Chemical dataFormula C25H28N6OMol. mass 428.53SMILES eMolecules & PubChemPharmacokinetic dataBioavailability 60–80%Metabolism Hepatic (CYP2C9)Half life avapro tablets 150 mg hoursExcretion Renal 20%, faecal 65%Therapeutic considerationsLicence data EU, USPregnancy cat. EU.

851-60. PMID 11565517.^ Rossi S, editor. Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3 avapro tablets 150 mg Wikipedia, avapro tablets 150 mg free encyclopedia(Redirected from Avapro)Jump to: navigation, searchIrbesartanSystematic (IUPAC) avapro tablets 150 mg number 138402-11-6ATC code C09CA04PubChem 3749DrugBank APRD00413Chemical dataFormula C25H28N6OMol. mass 428.53SMILES eMolecules & PubChemPharmacokinetic dataBioavailability 60–80%Metabolism Hepatic (CYP2C9)Half life 11–15 hoursExcretion Renal 20%, faecal 65%Therapeutic considerationsLicence data EU, USPregnancy cat. D (Au)Legal status S4 (Au), POM (UK), ?-only (U.S.)Routes OralIrbesartan (INN) avapro tablets 150 mg /?rb??s?rt?n/) is an angiotensin II receptor avapro tablets 150 mg irbesartan is indicated for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). avapro tablets 150 mg is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names.

Renal 20%, faecal 65%Therapeutic considerationsLicence data EU, USPregnancy cat. D (Au)Legal status D.